Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Karyopharm Therapeutics Inc.

NASDAQ: KPTIQ · Life Sciences · 5 alerts · CIK 1503802

Share price
$0.0286Close, Nov 16
Market cap
$649K
Shares outstanding
22.68MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Karyopharm Therapeutics Inc. filings on SEC EDGAR ↗

6:05 AM ET 8-K
Bankruptcy & Restructuring

Karyopharm Therapeutics Bankruptcy & Restructuring

Karyopharm Therapeutics Inc. and its subsidiary filed voluntary petitions for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the Southern District of Texas. The company entered into a Restructuring Support Agreement with 100% of its funded debt holders and Ayrmid Ltd., which will serve as a stalking horse bidder for a merger with the reorganized company. The company will continue operations as a debtor-in-possession while seeking a court-supervised sale or reorganization to maximize stakeholder value.

Counterparty
Ayrmid Ltd.
9:22 AM ET 8-K
Bankruptcy & Restructuring

Karyopharm Therapeutics Bankruptcy & Restructuring

Karyopharm Therapeutics has filed for voluntary Chapter 11 bankruptcy protection to implement a Restructuring Support Agreement and a planned merger with Ayrmid Ltd. The company secured $55 million in debtor-in-possession (DIP) financing to maintain operations during the court-supervised sale process. Existing equity holders are warned that their common and preferred stock will likely have no value and experience a complete loss.

Counterparty
Ayrmid Ltd.
4:15 PM ET 8-K
Loan & Debt

Karyopharm Therapeutics Debt Financing Update

Karyopharm Therapeutics has extended its existing Forbearance Agreement and Limited Waiver to Indentures from October 22, 2026, to November 1, 2026. This extension provides the company additional time to address its debt obligations while lenders agree to refrain from exercising certain rights or remedies during this period.

Term
through Nov 1, 2026
7:30 AM ET 8-K
Loan & Debt

Karyopharm Therapeutics Debt Financing Update

Karyopharm Therapeutics Inc. has extended its existing forbearance period under a Forbearance Agreement and Limited Waiver to Indentures. The expiration date of the forbearance period was moved from October 15, 2026, to October 22, 2026, providing the company additional time to address its debt obligations.

4:06 PM ET 8-K
Other 8-K Filing

Karyopharm Therapeutics Other 8-K Filing

Karyopharm Therapeutics issued 20,000 shares of a newly created Series A Convertible Perpetual Preferred Stock to satisfy $20.0 million in fees owed under a forbearance agreement with its lenders. The preferred stock is convertible into common stock at $1.62 per share, though initial conversions are capped at 19.99% of outstanding shares pending stockholder approval.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.